Big Pharma Investment in Protein Degraders and the Future of Drug Discovery

Published :   19 Oct 2026  |  Author :  Aditi Shivarkar, Aman Singh  | 
 |  Copy Copy   Print Print

Big pharmaceutical companies are investing billions in protein degrader technology to target disease related proteins that conventional drugs struggle to control. This emerging approach could expand treatment opportunities for cancer, autoimmune disorders, and neurological diseases, although clinical and safety challenges remain.

The pharmaceutical industry is entering a new phase of drug discovery as researchers explore innovative ways to treat diseases that have remained difficult to manage with conventional medicines. For decades, many treatments have focused on blocking the activity of disease-related proteins. However, some proteins lack suitable binding sites, while others develop mutations that allow disease to resist existing therapies.

Protein degrader drugs are emerging as a promising alternative. Instead of simply blocking a problematic protein, these medicines are designed to direct it toward the cell’s natural waste-disposal machinery, where it can be broken down and removed. This approach could open new possibilities for treating certain cancers, autoimmune conditions, and neurological disorders.

According to the Wall Street Journal, pharmaceutical companies have committed more than $5 billion to protein degrader-related deals between 2021 and 2026, reflecting growing interest in this technology. More than 200 protein degrader drugs are reportedly under investigation worldwide.

The investment raised an important question: could protein degraders help pharmaceutical companies develop treatments for diseases that have resisted traditional drug discovery, and what challenges must researchers overcome before this technology reaches more patients?

Understanding Protein Degrader Technology

Proteins perform essential functions through the human body, including regulating cell growth, controlling immune responses, and supporting communication between cells. However, certain proteins can contribute to diseases when they become overactive, malfunction, accumulate abnormally, or support uncontrolled cellular growth.

Traditional small-molecule medicines often work by attaching to a protein and inhibiting its activity. Although this approach has delivered significant medical advances, it is not suitable for every disease-related protein. Some proteins lack accessible binding sites, while others can continue contributing to disease through functions that are difficult to block completely.

Protein degraders take a different approach. These compounds bring a target protein into contact with the cell’s protein-disposal machinery, commonly involving the ubiquitine-proteasome system. The machinery marks the protein for destruction, allowing the cell to break it down.

Two important approaches are proteolysis-targeting chimeras, commonly known as PROTACs, and molecular glues. PROTACs typically use one part of a molecule to bind the disease-related us eone part of a molecule to bind thr disease-related protein and another to recruit the cellular machinery responsible for its degradation. Molecular glues promote interactions between proteins that might normally associate, helping initiate the degradation process.

By removing the problematic protein rather than merely inhibiting it, these technologies may offer a different way to address disease biology. However, their effectiveness depends on the targets, the drug’s ability to enter relevant cells, and the body’s capacity to carry out the degradation process.

Why Big Pharma is Investing Billions in Protein Degraders

Targeting Previously Difficult-to-Treat Proteins

One of the strongest reasons for pharmaceutical investment is the possibility of addressing proteins that conventional medicines struggle to control.

Some disease-driving proteins lack the structural features needed for effective inhibition. Others interact with several biological pathways, making it difficult to control their effects using traditional drugs.

Protein degraders could expand the range of proteins researchers can target by focusing on removing them instead of blocking a specific functional site. This may be particularly valuable in diseases where a problematic protein continues to support abnormal cell activity despite existing treatment.

Nevertheless, not every difficult-to-target protein can be degraded. Researchers must identify suitable molecular interactions and establish that the protein can be removed safely and effectively.

Addressing Drug Resistance in Cancer

Cancer is an important area of protein degrader research because tumors can develop resistance to medicines that initially control their growth.

Certain cancers depend on specific proteins for survival and proliferation. When conventional treatments inhibit these proteins, cancer cells may require mutations or activate pathways that reduce treatments effectiveness.

Protein degradation could offer another strategy by eliminating selected proteins rather than simply suppressing their activity. Researchers are investigating whether this approach can overcome some resistance mechanisms and improve treatment options for patients whose cancers have progressed after previous therapies.

However, successful degradation does not automatically guarantee better clinical outcomes. Tumors may develop resistance through other biological mechanisms, and the effectiveness of each drug will depend on the cancer type and the molecular charateristics of individual patients.

Expanding Treatment Opportunities Beyond Oncology

Although cancer research has attracted considerable attention, protein degraders could have applications across several therapeutic areas.

In autoimmune and inflammatory disease, researchers are investigating whether removing selected proteins involved in abnormal immune responses could provide benefit when existing medicines do not adequately control disease activity or when patients experience insufficient responses to established therapies.

Neurological disorders also represent an area of scientific interest. Some conditions involve the accumulation or abnormal activity of particular proteins in the brain. Developing treatments that selectively remove these proteins could provide a new direction for research.

However, neurological applications face additional challenges, including the need for medicines to reach the brain, identify appropriate targets, and avoid disrupting proteins required for healthy neurological function.

These applications remain dependent on clinical evidence. Potential benefits across multiple diseases should not be confused with proven effectiveness in patients.

The Role of Pharmaceutical Partnerships and Investment

The growing interest in protein degradation is encouraging pharmaceutical companies to establish partnerships with biotechnology firms that specialize in targeted protein degradation.

Developing these medicines requires expertise in molecular design and clinical development. Smaller biotechnology companies often focus on creating new degrader platforms, while larger pharmaceutical companies can contribute funding, development infrastructure, regulatory experience, and global commercialization capabilities.

Such collaborations can help accelerate drug development and distribute the financial risks associated with experimental technologies.

Roche's 2026 collaboration with Nurix Therapeutics illustrates this trend. The companies agreed to co-develop and co-commercialize bexobrutideg, an investigational Bruton’s tyrosine kinase (BTK) degrader, with potential applications in blood cancers and additional research opportunities in immunology and neurology.

The collaboration highlights how established pharmaceutical companies are using partnerships to access specialized research platforms and expand their development pipelines.

However, large investments do not guarantee successful medicines. Commercial agreements often include upfront payments, milestone payments, and potential royalties, meaning the headline value of a deal may depend on future development and sales achievements.

How Protein Degraders Could Transform Drug Development

Moving From Protein Inhibition to Protein Removal

The most important difference between conventional inhibitors and protein degraders is their intended mechanism of action.

An inhibitor generally suppresses a protein's activity while the protein remains present in the cell. A degrader aims to remove the selected protein through the cell's natural disposal system.

This difference could be useful when a disease-related protein performs several harmful functions or when blocking only one function does not provide sufficient disease control.Protein degraders may also act through a catalytic mechanism, allowing a degrader molecule to participate in multiple degradation events. However, this does not mean every degrader requires a lower dose or produces fewer side effects than conventional medicines. These advantages must be established for each drug through research and clinical testing.

Supporting More Targeted Treatment Strategies

Protein degrader development could support more precise treatment strategies by focusing on proteins that play important roles in specific diseases.

Advances in molecular biology and drug-design technologies are helping researchers identify disease-related targets and design compounds that encourage the required protein interactions.

Artificial intelligence and computational tools may further support this work by helping scientists evaluate molecular structures, predict interactions, and prioritize promising drug candidates.

Nevertheless, computer-based predictions must be confirmed experimentally. Researchers still need to establish whether a candidate selectively degrades the intended protein, reaches the appropriate tissues, and produces meaningful benefits without unacceptable toxicity.

Creating New Opportunities for Personalized Medicine

Patients with the same diagnosis may have different genetic mutations, disease mechanisms, and treatment responses. Protein degraders could eventually contribute to more individualized treatment approaches by targeting proteins associated with particular molecular characteristics.

For example, a degrader designed for a specific cancer-related protein may be most suitable for patients whose tumors depend on that protein or contain a relevant molecular alteration.

This approach could strengthen the role of biomarker testing in treatment selection. It may also help researchers identify patient groups most likely to benefit from experimental therapies.

However, personalized treatment will require validated biomarkers, reliable diagnostic testing, and clinical evidence demonstrating which patients benefit from particular drugs.

Key Challenges Facing Protein Degrader Development

Selectivity and Potential Side Effects

Protein degraders must identify their intended targets without causing excessive disruption to healthy proteins. Unintended protein degradation could interfere with normal cellular functions and create safety concerns

Researchers must carefully evaluate target selectivity, dosage, tissue distribution, and potential toxic effects during development.

Drug Delivery and Cellular Access

Some degrader molecules are relatively large or chemically complex, which can create challenges involving absorption, distribution, and penetration into cells.

Reaching tissues such as the brain may be particularly difficult. Scientists must develop molecules with suitable drug-like properties while maintaining effective target binding and degradation activity.

Clinical Evidence and Regulatory Approval

Promising laboratory results do not necessarily translate into successful treatments. Clinical trials must establish whether protein degraders provide meaningful improvements in disease outcomes and offer an acceptable safety profile.

Drug developers must also determine suitable doses, identify relevant patient populations, and compare new treatments with existing standards of care.

Manufacturing Costs and Commercial Viability

Developing and manufacturing complex drug candidates can require substantial investment in research, production processes, analytical testing, and quality control.

Companies must establish scalable manufacturing methods and demonstrate that commercial production can meet regulatory requirements. Long development timelines and uncertain clinical outcomes can also affect the financial returns associated with these investments.

What Pharmaceutical Companies Should Focus on Next

To turn protein degrader research into viable treatments, pharmaceutical companies must prioritize several areas.

First, researchers should identify disease-related proteins that can be degraded safely and whose removal is likely to produce meaningful clinical benefits.

Second, companies should improve molecular design to strengthen selectivity, drug delivery, stability, and degradation efficiency.

Third, clinical development should focus on clearly defined patient populations and measurable outcomes. Biomarker-based selection may help researchers determine whether a treatment is effective for patients with particular molecular characteristics.

Fourth, pharmaceutical and biotechnology partnerships should combine complementary expertise while maintaining realistic expectations about development timelines and commercial returns.

Finally, companies must evaluate long-term safety, manufacturing feasibility, regulatory requirements, and the ability of new treatments to provide advantages over existing medicines.

Conclusion

Big pharma's investment of more than $5 billion in protein degrader-related deals reflects growing confidence in a technology that could expand the boundaries of drug discovery.

By directing disease-related proteins toward the body's natural protein-disposal machinery, degraders offer a different approach to treating conditions that conventional medicines may struggle to control.

Cancer, autoimmune disorders, and neurological diseases represent important areas of investigation. Partnerships between pharmaceutical companies and specialized biotechnology firms are also helping advance research, develop new candidates, and explore additional therapeutic applications.

However, significant challenges remain. Selectivity, drug delivery, clinical effectiveness, safety, manufacturing complexity, and commercial viability will determine which candidates can become successful medicines.

Protein degraders are not a universal solution to previously untreatable diseases, and many potential applications remain under investigation. Their long-term significance will depend on whether clinical trials demonstrate clear benefits for patients.

Ultimately, this technology could become an important addition to modern medicine if researchers can translate its scientific potential into safe, effective, and accessible treatments.

About the Authors

Aditi Shivarkar

Aditi Shivarkar

Aditi, Vice President at Precedence Research, brings over 15 years of expertise at the intersection of technology, innovation, and strategic market intelligence. A visionary leader, she excels in transforming complex data into actionable insights that empower businesses to thrive in dynamic markets. Her leadership combines analytical precision with forward-thinking strategy, driving measurable growth, competitive advantage, and lasting impact across industries.

Aman Singh

Aman Singh

Aman Singh with over 13 years of progressive expertise at the intersection of technology, innovation, and strategic market intelligence, Aman Singh stands as a leading authority in global research and consulting. Renowned for his ability to decode complex technological transformations, he provides forward-looking insights that drive strategic decision-making. At Precedence Research, Aman leads a global team of analysts, fostering a culture of research excellence, analytical precision, and visionary thinking.

Piyush Pawar

Piyush Pawar

Piyush Pawar brings over a decade of experience as Senior Manager, Sales & Business Growth, acting as the essential liaison between clients and our research authors. He translates sophisticated insights into practical strategies, ensuring client objectives are met with precision. Piyush’s expertise in market dynamics, relationship management, and strategic execution enables organizations to leverage intelligence effectively, achieving operational excellence, innovation, and sustained growth.